Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Arch Biopartners.

    Client Virtual Booth

    ARCH BIOPARTNERS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Arch Biopartners
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    27 St. Clair Avenue East P.O. Box 305 Toronto, Ontario, M4T 2M5 Canada
    Telephone
    Telephone
    +1 647 428 7031
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://archbiopartners.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arch-biopartners-inc-foiff-
    Twitter
    Twitter
    https://twitter.com/archbiopartners

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: University of Calgary

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 15, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-acute Kidney Injury

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 07, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Has Pre-IND Meeting with FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

    Details:

    Cilastatin is an enzymatic dipeptidase-1 (DPEP-1) inhibitor, small molecule drug. It is being evaluated for the treatment of toxin related acute kidney injury.


    Lead Product(s): Cilastatin

    Therapeutic Area: Nephrology Product Name: Undisclosed

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 27, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under phase 2 clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 10, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associ...

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under phase 2 clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSA...

    Details:

    Metablok (LSALT peptide) targets the dipeptidase-1 (DPEP-1) pathway. It is under phase 2 clinical development for the treatment of cardiac surgery-associated acute kidney injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 21, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

    Details:

    Metablok (LSALT peptide) is a DPEP 1 inhibitor peptide drug candidate, which is currently being evaluated for the treatment of Surgery Associated-Acute Kidney Injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 13, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LS...

    Details:

    Metablok (LSALT peptide) is a dipeptidase-1 (DPEP-1) inhibitor which has the ability to block the inflammatory response triggered in the lung and liver with lipopolysaccharide induced inflammation and in the kidney with ischemia/reperfusion induced injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 22, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

    Details:

    Metablok (LSALT peptide) is a dipeptidase-1 (DPEP-1) inhibitor which has the ability to block the inflammatory response triggered in the lung and liver with lipopolysaccharide induced inflammation and Acute Kidney Injury.


    Lead Product(s): LSALT Peptide

    Therapeutic Area: Nephrology Product Name: Metablok

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 27, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search